Influence of GLP-1 Receptor Agonists on Surgical and Nonsurgical Treatment of Ankle Osteoarthritis.

Le Y, Thai S, Siragusa J, Elsabbagh L, Beeram I, Hsu N, Thompson J, Aiyer A

Foot & ankle specialist17 Aug 2026

PMID42609010DOI10.1177/19386400261471652PepBankPUB-42609010

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study27

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone27

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In adults with diabetes, pooled GLP-1 use was linked to greater arthroscopy risk than non-use.
In plain wordsIn adults with diabetes, pooled GLP-1 use was linked to higher arthroscopy risk versus non-use.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseArthroscopy in diabetes
Study
n = 16,234
Comparator
GLP-1 non-users
Outcome group
Bone and joint · Musculoskeletal
Measurements
Hazard ratio
1.9 ratio
diabetic cohort, GLP-1 users versus non-users
Source sentences
Summary
In the diabetic cohort, GLP-1 use was associated with increased risk of arthroscopy (HR = 1.9, 95% CI = 1.2-3.2) but not joint injection or TAA.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4260901010
02HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with diabetes, pooled GLP-1 use was linked to greater arthroscopy risk than non-use.
In plain wordsIn adults with diabetes, pooled GLP-1 use was linked to higher arthroscopy risk versus non-use.
Peptide
Liraglutide
Outcome
IncreaseArthroscopy in diabetes
Study
n = 16,234
Comparator
GLP-1 non-users
Outcome group
Bone and joint · Musculoskeletal
Measurements
Hazard ratio
1.9 ratio
diabetic cohort, GLP-1 users versus non-users
Source sentences
Summary
In the diabetic cohort, GLP-1 use was associated with increased risk of arthroscopy (HR = 1.9, 95% CI = 1.2-3.2) but not joint injection or TAA.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4260901011
03HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with diabetes, pooled GLP-1 use was linked to greater arthroscopy risk than non-use.
In plain wordsIn adults with diabetes, pooled GLP-1 use was linked to higher arthroscopy risk versus non-use.
Peptide
Semaglutide
Outcome
IncreaseArthroscopy in diabetes
Study
n = 16,234
Comparator
GLP-1 non-users
Outcome group
Bone and joint · Musculoskeletal
Measurements
Hazard ratio
1.9 ratio
diabetic cohort, GLP-1 users versus non-users
Source sentences
Summary
In the diabetic cohort, GLP-1 use was associated with increased risk of arthroscopy (HR = 1.9, 95% CI = 1.2-3.2) but not joint injection or TAA.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4260901012
04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In adults with diabetes, pooled GLP-1 use was not linked to different ankle injection risk versus non-use.
In plain wordsIn adults with diabetes, pooled GLP-1 use was linked to no significant difference in ankle injection risk versus non-use.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeAnkle injection in diabetes
Study
n = 16,234
Comparator
GLP-1 non-users
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the diabetic cohort, GLP-1 use was associated with increased risk of arthroscopy (HR = 1.9, 95% CI = 1.2-3.2) but not joint injection or TAA.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4260901013
05HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with diabetes, pooled GLP-1 use was not linked to different ankle injection risk versus non-use.
In plain wordsIn adults with diabetes, pooled GLP-1 use was linked to no significant difference in ankle injection risk versus non-use.
Peptide
Liraglutide
Outcome
No significant changeAnkle injection in diabetes
Study
n = 16,234
Comparator
GLP-1 non-users
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the diabetic cohort, GLP-1 use was associated with increased risk of arthroscopy (HR = 1.9, 95% CI = 1.2-3.2) but not joint injection or TAA.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4260901014
06HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with diabetes, pooled GLP-1 use was not linked to different ankle injection risk versus non-use.
In plain wordsIn adults with diabetes, pooled GLP-1 use was linked to no significant difference in ankle injection risk versus non-use.
Peptide
Semaglutide
Outcome
No significant changeAnkle injection in diabetes
Study
n = 16,234
Comparator
GLP-1 non-users
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the diabetic cohort, GLP-1 use was associated with increased risk of arthroscopy (HR = 1.9, 95% CI = 1.2-3.2) but not joint injection or TAA.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4260901015
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In adults with diabetes, pooled GLP-1 use was not linked to different ankle arthroplasty risk versus non-use.
In plain wordsIn adults with diabetes, pooled GLP-1 use was linked to no significant difference in ankle replacement risk versus non-use.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeAnkle arthroplasty in diabetes
Study
n = 16,234
Comparator
GLP-1 non-users
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the diabetic cohort, GLP-1 use was associated with increased risk of arthroscopy (HR = 1.9, 95% CI = 1.2-3.2) but not joint injection or TAA.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4260901016
08HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with diabetes, pooled GLP-1 use was not linked to different ankle arthroplasty risk versus non-use.
In plain wordsIn adults with diabetes, pooled GLP-1 use was linked to no significant difference in ankle replacement risk versus non-use.
Peptide
Liraglutide
Outcome
No significant changeAnkle arthroplasty in diabetes
Study
n = 16,234
Comparator
GLP-1 non-users
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the diabetic cohort, GLP-1 use was associated with increased risk of arthroscopy (HR = 1.9, 95% CI = 1.2-3.2) but not joint injection or TAA.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4260901017
09HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with diabetes, pooled GLP-1 use was not linked to different ankle arthroplasty risk versus non-use.
In plain wordsIn adults with diabetes, pooled GLP-1 use was linked to no significant difference in ankle replacement risk versus non-use.
Peptide
Semaglutide
Outcome
No significant changeAnkle arthroplasty in diabetes
Study
n = 16,234
Comparator
GLP-1 non-users
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the diabetic cohort, GLP-1 use was associated with increased risk of arthroscopy (HR = 1.9, 95% CI = 1.2-3.2) but not joint injection or TAA.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4260901018
10HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In adults with diabetes, pooled GLP-1 users had greater BMI reductions than non-users.
In plain wordsIn adults with diabetes, pooled GLP-1 use was linked to greater BMI reductions versus non-use.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBMI in diabetes
Study
n = 16,234
Comparator
GLP-1 non-users
Outcome group
Body weight · Metabolic and weight
Measurements
BMI change over 5 years
−2.1 kg/m2
diabetic cohort, GLP-1 users
BMI change over 5 years
−1.7 kg/m2
diabetic cohort, non-users
Source sentences
Summary
Over 5 years, GLP-1 users achieved greater reductions in BMI compared with non-users (obese cohort: -2.7 vs -1.6 kg/m²; diabetic cohort: -2.1 vs -1.7 kg/m²; both P < .01).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4260901022
11HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with diabetes, pooled GLP-1 users had greater BMI reductions than non-users.
In plain wordsIn adults with diabetes, pooled GLP-1 use was linked to greater BMI reductions versus non-use.
Peptide
Liraglutide
Outcome
DecreaseBMI in diabetes
Study
n = 16,234
Comparator
GLP-1 non-users
Outcome group
Body weight · Metabolic and weight
Measurements
BMI change over 5 years
−2.1 kg/m2
diabetic cohort, GLP-1 users
BMI change over 5 years
−1.7 kg/m2
diabetic cohort, non-users
Source sentences
Summary
Over 5 years, GLP-1 users achieved greater reductions in BMI compared with non-users (obese cohort: -2.7 vs -1.6 kg/m²; diabetic cohort: -2.1 vs -1.7 kg/m²; both P < .01).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4260901023
12HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with diabetes, pooled GLP-1 users had greater BMI reductions than non-users.
In plain wordsIn adults with diabetes, pooled GLP-1 use was linked to greater BMI reductions versus non-use.
Peptide
Semaglutide
Outcome
DecreaseBMI in diabetes
Study
n = 16,234
Comparator
GLP-1 non-users
Outcome group
Body weight · Metabolic and weight
Measurements
BMI change over 5 years
−2.1 kg/m2
diabetic cohort, GLP-1 users
BMI change over 5 years
−1.7 kg/m2
diabetic cohort, non-users
Source sentences
Summary
Over 5 years, GLP-1 users achieved greater reductions in BMI compared with non-users (obese cohort: -2.7 vs -1.6 kg/m²; diabetic cohort: -2.1 vs -1.7 kg/m²; both P < .01).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4260901024
13HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In adults with diabetes, HbA1c fell in both pooled GLP-1 users and non-users, with a slightly smaller fall in users.
In plain wordsIn adults with diabetes, HbA1c improved in both groups, but pooled GLP-1 use was linked to a slightly smaller improvement than non-use.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c
Study
n = 16,234
Comparator
GLP-1 non-users
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c change
−6%
non-users
HbA1c change
−5.5%
GLP-1 users
Source sentences
Summary
HbA1c improved significantly in both diabetic groups, with slightly greater reduction in non-users (-6.0% vs -5.5%, P < .01)
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4260901025
14HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with diabetes, HbA1c fell in both pooled GLP-1 users and non-users, with a slightly smaller fall in users.
In plain wordsIn adults with diabetes, HbA1c improved in both groups, but pooled GLP-1 use was linked to a slightly smaller improvement than non-use.
Peptide
Liraglutide
Outcome
IncreaseHbA1c
Study
n = 16,234
Comparator
GLP-1 non-users
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c change
−6%
non-users
HbA1c change
−5.5%
GLP-1 users
Source sentences
Summary
HbA1c improved significantly in both diabetic groups, with slightly greater reduction in non-users (-6.0% vs -5.5%, P < .01)
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4260901026
15HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with diabetes, HbA1c fell in both pooled GLP-1 users and non-users, with a slightly smaller fall in users.
In plain wordsIn adults with diabetes, HbA1c improved in both groups, but pooled GLP-1 use was linked to a slightly smaller improvement than non-use.
Peptide
Semaglutide
Outcome
IncreaseHbA1c
Study
n = 16,234
Comparator
GLP-1 non-users
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c change
−6%
non-users
HbA1c change
−5.5%
GLP-1 users
Source sentences
Summary
HbA1c improved significantly in both diabetic groups, with slightly greater reduction in non-users (-6.0% vs -5.5%, P < .01)
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4260901027
16HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In adults with obesity, pooled GLP-1 use was linked to lower ankle injection risk than non-use.
In plain wordsIn adults with obesity, pooled GLP-1 use was linked to lower ankle injection risk versus non-use.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseAnkle injection in obesity
Study
n = 6,178
Comparator
GLP-1 non-users
Outcome group
Bone and joint · Musculoskeletal
Measurements
Hazard ratio
0.8 ratio
obese cohort, GLP-1 users versus non-users
Source sentences
Summary
In the obese cohort, GLP-1 users had a lower risk of ankle joint injection (HR = 0.8, 95% CI = 0.6-0.9) and TAA (HR = 0.5, 95% CI = 0.3-0.9), while risk of arthroscopy was not significantly different.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4260901001
17HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with obesity, pooled GLP-1 use was linked to lower ankle injection risk than non-use.
In plain wordsIn adults with obesity, pooled GLP-1 use was linked to lower ankle injection risk versus non-use.
Peptide
Liraglutide
Outcome
DecreaseAnkle injection in obesity
Study
n = 6,178
Comparator
GLP-1 non-users
Outcome group
Bone and joint · Musculoskeletal
Measurements
Hazard ratio
0.8 ratio
obese cohort, GLP-1 users versus non-users
Source sentences
Summary
In the obese cohort, GLP-1 users had a lower risk of ankle joint injection (HR = 0.8, 95% CI = 0.6-0.9) and TAA (HR = 0.5, 95% CI = 0.3-0.9), while risk of arthroscopy was not significantly different.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4260901002
18HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with obesity, pooled GLP-1 use was linked to lower ankle injection risk than non-use.
In plain wordsIn adults with obesity, pooled GLP-1 use was linked to lower ankle injection risk versus non-use.
Peptide
Semaglutide
Outcome
DecreaseAnkle injection in obesity
Study
n = 6,178
Comparator
GLP-1 non-users
Outcome group
Bone and joint · Musculoskeletal
Measurements
Hazard ratio
0.8 ratio
obese cohort, GLP-1 users versus non-users
Source sentences
Summary
In the obese cohort, GLP-1 users had a lower risk of ankle joint injection (HR = 0.8, 95% CI = 0.6-0.9) and TAA (HR = 0.5, 95% CI = 0.3-0.9), while risk of arthroscopy was not significantly different.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4260901003
19HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In adults with obesity, pooled GLP-1 use was linked to lower ankle arthroplasty risk than non-use.
In plain wordsIn adults with obesity, pooled GLP-1 use was linked to lower ankle replacement risk versus non-use.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseAnkle arthroplasty in obesity
Study
n = 6,178
Comparator
GLP-1 non-users
Outcome group
Bone and joint · Musculoskeletal
Measurements
Hazard ratio
0.5 ratio
obese cohort, GLP-1 users versus non-users
Source sentences
Summary
In the obese cohort, GLP-1 users had a lower risk of ankle joint injection (HR = 0.8, 95% CI = 0.6-0.9) and TAA (HR = 0.5, 95% CI = 0.3-0.9), while risk of arthroscopy was not significantly different.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4260901004
20HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with obesity, pooled GLP-1 use was linked to lower ankle arthroplasty risk than non-use.
In plain wordsIn adults with obesity, pooled GLP-1 use was linked to lower ankle replacement risk versus non-use.
Peptide
Liraglutide
Outcome
DecreaseAnkle arthroplasty in obesity
Study
n = 6,178
Comparator
GLP-1 non-users
Outcome group
Bone and joint · Musculoskeletal
Measurements
Hazard ratio
0.5 ratio
obese cohort, GLP-1 users versus non-users
Source sentences
Summary
In the obese cohort, GLP-1 users had a lower risk of ankle joint injection (HR = 0.8, 95% CI = 0.6-0.9) and TAA (HR = 0.5, 95% CI = 0.3-0.9), while risk of arthroscopy was not significantly different.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4260901005
21HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with obesity, pooled GLP-1 use was linked to lower ankle arthroplasty risk than non-use.
In plain wordsIn adults with obesity, pooled GLP-1 use was linked to lower ankle replacement risk versus non-use.
Peptide
Semaglutide
Outcome
DecreaseAnkle arthroplasty in obesity
Study
n = 6,178
Comparator
GLP-1 non-users
Outcome group
Bone and joint · Musculoskeletal
Measurements
Hazard ratio
0.5 ratio
obese cohort, GLP-1 users versus non-users
Source sentences
Summary
In the obese cohort, GLP-1 users had a lower risk of ankle joint injection (HR = 0.8, 95% CI = 0.6-0.9) and TAA (HR = 0.5, 95% CI = 0.3-0.9), while risk of arthroscopy was not significantly different.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4260901006
22HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In adults with obesity, arthroscopy risk did not differ significantly between pooled GLP-1 users and non-users.
In plain wordsIn adults with obesity, pooled GLP-1 use was linked to no significant difference in arthroscopy risk versus non-use.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeArthroscopy in obesity
Study
n = 6,178
Comparator
GLP-1 non-users
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the obese cohort, GLP-1 users had a lower risk of ankle joint injection (HR = 0.8, 95% CI = 0.6-0.9) and TAA (HR = 0.5, 95% CI = 0.3-0.9), while risk of arthroscopy was not significantly different.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4260901007
23HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with obesity, arthroscopy risk did not differ significantly between pooled GLP-1 users and non-users.
In plain wordsIn adults with obesity, pooled GLP-1 use was linked to no significant difference in arthroscopy risk versus non-use.
Peptide
Liraglutide
Outcome
No significant changeArthroscopy in obesity
Study
n = 6,178
Comparator
GLP-1 non-users
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the obese cohort, GLP-1 users had a lower risk of ankle joint injection (HR = 0.8, 95% CI = 0.6-0.9) and TAA (HR = 0.5, 95% CI = 0.3-0.9), while risk of arthroscopy was not significantly different.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4260901008
24HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with obesity, arthroscopy risk did not differ significantly between pooled GLP-1 users and non-users.
In plain wordsIn adults with obesity, pooled GLP-1 use was linked to no significant difference in arthroscopy risk versus non-use.
Peptide
Semaglutide
Outcome
No significant changeArthroscopy in obesity
Study
n = 6,178
Comparator
GLP-1 non-users
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the obese cohort, GLP-1 users had a lower risk of ankle joint injection (HR = 0.8, 95% CI = 0.6-0.9) and TAA (HR = 0.5, 95% CI = 0.3-0.9), while risk of arthroscopy was not significantly different.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4260901009
25HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In adults with obesity, pooled GLP-1 users had greater BMI reductions than non-users.
In plain wordsIn adults with obesity, pooled GLP-1 use was linked to greater BMI reductions versus non-use.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBMI in obesity
Study
n = 6,178
Comparator
GLP-1 non-users
Outcome group
Body weight · Metabolic and weight
Measurements
BMI change over 5 years
−2.7 kg/m2
obese cohort, GLP-1 users
BMI change over 5 years
−1.6 kg/m2
obese cohort, non-users
Source sentences
Summary
Over 5 years, GLP-1 users achieved greater reductions in BMI compared with non-users (obese cohort: -2.7 vs -1.6 kg/m²; diabetic cohort: -2.1 vs -1.7 kg/m²; both P < .01).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4260901019
26HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with obesity, pooled GLP-1 users had greater BMI reductions than non-users.
In plain wordsIn adults with obesity, pooled GLP-1 use was linked to greater BMI reductions versus non-use.
Peptide
Liraglutide
Outcome
DecreaseBMI in obesity
Study
n = 6,178
Comparator
GLP-1 non-users
Outcome group
Body weight · Metabolic and weight
Measurements
BMI change over 5 years
−2.7 kg/m2
obese cohort, GLP-1 users
BMI change over 5 years
−1.6 kg/m2
obese cohort, non-users
Source sentences
Summary
Over 5 years, GLP-1 users achieved greater reductions in BMI compared with non-users (obese cohort: -2.7 vs -1.6 kg/m²; diabetic cohort: -2.1 vs -1.7 kg/m²; both P < .01).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4260901020
27HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with obesity, pooled GLP-1 users had greater BMI reductions than non-users.
In plain wordsIn adults with obesity, pooled GLP-1 use was linked to greater BMI reductions versus non-use.
Peptide
Semaglutide
Outcome
DecreaseBMI in obesity
Study
n = 6,178
Comparator
GLP-1 non-users
Outcome group
Body weight · Metabolic and weight
Measurements
BMI change over 5 years
−2.7 kg/m2
obese cohort, GLP-1 users
BMI change over 5 years
−1.6 kg/m2
obese cohort, non-users
Source sentences
Summary
Over 5 years, GLP-1 users achieved greater reductions in BMI compared with non-users (obese cohort: -2.7 vs -1.6 kg/m²; diabetic cohort: -2.1 vs -1.7 kg/m²; both P < .01).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with obesity (body mass index [BMI] ≥30 kg/m²) or T2DM (ICD-10: E11) were identified between 2016 and 2020.
Summary · context
Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4260901021

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 5Current
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 4
22 Oct 2026, 02:25 UTC
Study results updated
Versions 2 to 3
21 Oct 2026, 18:59 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.